Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kantor

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Neurology and Therapy|December 10, 2017
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory MedicineDaniel Kantor, Jeremy R Bright, Jeri Burtchell
Neurology and Therapy|December 16, 2017
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Patient EducationDaniel Kantor, Jeremy R Bright, Jeri Burtchell
The American Journal of Medicine|January 4, 2014
Novel therapeutics in multiple sclerosis management: clinical applicationsThomas Leist, Samuel F Hunter, Daniel Kantor, et al.
Neurology and Therapy|July 6, 2019
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease ProgressionJeri Burtchell, Kristen Fetty, Katelyn Miller, et al.
The Journal of Pain|September 27, 2015
Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy OutcomesDaniel Kantor, Sunil Panchal, Vikram Patel, et al.
Brain Communications|December 15, 2022
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trialDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Brain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Plos One|August 31, 2013
PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditionsBenjamin Rix Brooks, David Crumpacker, Jonathan Fellus, et al.
Current Medical Research and Opinion|April 25, 2020
Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetateBenjamin Greenberg, Steven Hall, Michael Grabner, et al.
Journal of the Neurological Sciences|April 23, 2017
Two decades of glatiramer acetate: From initial discovery to the current development of genericsBianca Weinstock-Guttman, Kavita V Nair, Joseph L Glajch, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Neurology and Therapy|December 10, 2017
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory MedicineDaniel Kantor, Jeremy R Bright, Jeri Burtchell
Neurology and Therapy|December 16, 2017
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Patient EducationDaniel Kantor, Jeremy R Bright, Jeri Burtchell
The American Journal of Medicine|January 4, 2014
Novel therapeutics in multiple sclerosis management: clinical applicationsThomas Leist, Samuel F Hunter, Daniel Kantor, et al.
Neurology and Therapy|July 6, 2019
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease ProgressionJeri Burtchell, Kristen Fetty, Katelyn Miller, et al.
The Journal of Pain|September 27, 2015
Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy OutcomesDaniel Kantor, Sunil Panchal, Vikram Patel, et al.
Brain Communications|December 15, 2022
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trialDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Brain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Plos One|August 31, 2013
PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditionsBenjamin Rix Brooks, David Crumpacker, Jonathan Fellus, et al.
Current Medical Research and Opinion|April 25, 2020
Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetateBenjamin Greenberg, Steven Hall, Michael Grabner, et al.
Journal of the Neurological Sciences|April 23, 2017
Two decades of glatiramer acetate: From initial discovery to the current development of genericsBianca Weinstock-Guttman, Kavita V Nair, Joseph L Glajch, et al.
Pageof 3